Safety and Efficacy of JKN2304 Inhalation Solution in Patients With Moderate to Severe COPD

The purpose of this Phase IIa study is to evaluate the safety, efficacy, and pharmacokinetics of JKN2304 Inhalation Solution in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD). The study is a multicenter, randomized, double-blind, placebo-controlled, and active-controlled (open-label) trial. Participants are randomized to receive JKN2304 (2 mg once daily or 2 mg twice daily), Placebo, or Formoterol Fumarate Inhalation Solution for a treatment period of 14 days.

NCT Number	NCT07450482
Lead Sponsor	Joincare Pharmaceutical Group Industry Co., Ltd Collaborators: Livzon Pharmaceutical Group Inc.
Conditions	COPD (Chronic Obstructive Pulmonary Disease), COPD
Enrollment	42 participants
Start Date	2025-07-22
Primary Completion	2025-09-25 (estimated)
Study Completion	2025-09-25 (estimated)
Updated on ClinicalTrials.gov	2026-03-04